FLT3 and acute myeloid leukemia: To test this hypothesis, 11 AML cell lines were subjected to 48 hour dose response assays with the following agents: FLT3 inhibitors (AC220 and sorafenib),[29, 30] DNA double strand break (DSB) inducers (etoposide, GO and vosaroxin),[31–33] the standard-of-care drug cytarabine and the hsp90 inhibitor 17-AAG.[34]